MedTrace Logo

Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

NCT03170206 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-02-12

No results posted yet for this study

Summary

This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.

The drugs involved in this study are:

* Palbociclib
* Binimetinib

Conditions

Interventions

DRUG

Binimetinib

Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.

DRUG

Palbociclib

It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6

Sponsors & Collaborators

Principal Investigators

  • Geoffrey Shapiro, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2023-02-28
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03170206 on ClinicalTrials.gov